Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
Commentary|Articles|December 12, 2014
Predicting Risk of Recurrence for Women With DCIS
Author(s)Eileen Rakovitch, MD
Eileen Rakovitch, MD, associate professor, radiation oncologist, Sunnybrook Health Sciences Centre, Toronto, Ontario, discusses predicting risk of recurrence in women with DCIS.
Advertisement
Clinical Pearls
Eileen Rakovitch, MD, associate professor, radiation oncologist, Sunnybrook Health Sciences Centre, Toronto, Ontario, discusses predicting risk of recurrence in women with DCIS.
- Oncotype DX DCIS Score was validated as a predictor of risk of recurrence among women treated with breast-conserving surgery alone for DCIS.
- Women with a low-risk DCIS Score had a significantly lower risk of recurrence.
- Every 50 point increase in DCIS Score was associated with a two-fold increase in risk of recurrence.
<<<
Advertisement
Related to this article
Preview the late-breaking studies at ESMO Congress 2026, from KRAS inhibitors and ADCs to bispecifics and perioperative immunotherapy across tumor types.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
3
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
4
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
5